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LIVER INJURY/REGENERATION
Polymerase c Gene POLG Determines the Risk of Sodium
Valproate-Induced Liver Toxicity
Joanna D. Stewart,1 Rita Horvath,1 Enrico Baruffini,2 Iliana Ferrero,2 Stefanie Bulst,3 Paul B. Watkins,4
Robert J. Fontana,5 Christopher P. Day,6 and Patrick F. Chinnery1,7
Sodium valproate (VPA) is widely used throughout the world to treat epilepsy, migraine,
chronic headache, bipolar disorder, and as adjuvant chemotherapy. VPA toxicity is an
uncommon but potentially fatal cause of idiosyncratic liver injury. Rare mutations in
POLG, which codes for the mitochondrial DNA polymerase c (polc), cause Alpers-Hutten-
locher syndrome (AHS). AHS is a neurometabolic disorder associated with an increased
risk of developing fatal VPA hepatotoxicity. We therefore set out to determine whether
common genetic variants in POLG explain why some otherwise healthy individuals de-
velop VPA hepatotoxicity. We carried out a prospective study of subjects enrolled in the
Drug Induced Liver Injury Network (DILIN) from 2004 to 2008 through five US centers.
POLG was sequenced and the functional consequences of VPA and novel POLG variants
were evaluated in primary human cell lines and the yeast model system Saccharomyces cer-
evisiae. Heterozygous genetic variation in POLG was strongly associated with VPA-
induced liver toxicity (odds ratio 5 23.6, 95% confidence interval [CI] 5 8.4-65.8, P 5
5.1 3 1027). This was principally due to the p.Q1236H substitution which compromised
polc function in yeast. Therapeutic doses of VPA inhibited human cellular proliferation
and high doses caused nonapoptotic cell death, which was not mediated through
mitochondrial DNA depletion, mutation, or a defect of fatty acid metabolism.
Conclusion: These findings implicate impaired liver regeneration in VPA toxicity and show
that prospective genetic testing of POLG will identify individuals at high risk of this
potentially fatal consequence of treatment. (HEPATOLOGY 2010;52:1791-1796)
O
ver 1 in 37,000 subjects exposed to sodium
valproate (valproic acid, VPA) develop idio-
syncratic liver toxicity, with the risk reaching
1 in 500 in young children on polytherapy.1
Increased awareness has contributed to a decline in
fatal VPA-induced liver failure,2 but the worldwide use
of VPA continues to increase through its use in other
clinical contexts. In addition to its use as a first-line
anticonvulsant, VPA is now in regular use for mi-
graine, bipolar disorder, chronic headache, and as adju-
vant chemotherapy. The prompt recognition of early
symptoms and immediate discontinuation of the drug
can prevent fulminant liver failure,2 but initial clinical
clues are often mild and nonspecific, making it diffi-
cult to identify individuals before significant liver dam-
age occurs. Liver biopsy characteristically reveals
microvesicular steatosis, and occasionally severe hepato-
cellular necrosis.3 Fever, rash, lymphadenopathy, and/
or peripheral eosinophilia are rarely present during
VPA hepatotoxicity, consistent with a direct toxic
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effect of the drug, rather than an immune-mediated
hypersensitivity reaction typical of other antiepileptic
drugs.4
The recent description of mutations in mitochondrial
DNA (mtDNA) polymerase c (POLG) as a major cause
of Alpers-Huttenlocher syndrome (AHS)5 provides a
clue to the underlying mechanism of VPA hepatotoxic-
ity. AHS is a rare childhood encephalopathy character-
ized by developmental delay and intractable epilepsy and
liver disease.6,7 Most cases have homozygous or com-
pound heterozygote mutations in POLG,5 and 1/3 of
AHS patients develop liver failure within 3 months of
exposure to VPA.8,9 This raises the possibility that a
common genetic variation in POLG predisposes individ-
uals to VPA-induced liver failure in the absence of a rec-
ognizable AHS-phenotype.
Patients and Methods
Participants. Patients with suspected VPA hepato-
toxicity were enrolled in the Drug Induced Liver
Injury Network (DILIN) from 2004 to 2008 through
five US centers involved at that time: North Carolina
at Chapel Hill, the Universities of Connecticut, Michi-
gan, Indiana, and California at San Francisco, and the
coordinating center at Duke Clinical Research Insti-
tute.3 All had one of the following on presentation:
jaundice or serum bilirubin >2.5 mg/dL and elevation
in alanine aminotransferase (ALT), aspartate amino
transferase (AST), or alkaline phosphatase (ALP); no
jaundice and serum bilirubin <2.5 mg/dL, but eleva-
tions in ALT or AST (>5-fold more than the upper
limit of normal [ULN]) or elevations in ALP (>2
ULN; Table 1). Laboratory and clinical data were cap-
tured by the site investigator who crafted a clinical
narrative describing the outcome. A committee of
three experienced hepatologists then reviewed the cases,
blind to the results of the study, and ranked the like-
lihood of causality on a scale of 1 (definite) to 5
(unlikely), as described.3 The study was conducted
with local ethical and Institutional Review Board ap-
proval in accordance with the Declaration of Helsinki.
Molecular Genetic Analysis. POLG exons and
flanking intronic regions (BC050559) were forward
and reverse sequenced (Applied Biosciences Big Dye
3.1, ABI3100). Cellular mtDNA levels were measured






























1 2 Caucasian þ 65 2 370 0.9 n.a.
2 5 Caucasian þ 219 c.3708G> T p.Q1236H 2 2471 2.7 1.9
3 9 Caucasian þ 74 n.a. 302 n.a. 1.2
4 15 Hispanic þ 2788 c.3708G> T p.Q1236H 3 525 3.9 1.0




2 287 26.7 4.4
6 16 Caucasian þ 13 5 69 1.0 1.4
7 19 Caucasian þ 48 3 1813 7.1 1.3
8 22 Caucasian þ 4 c.3708G> T p.Q1236H 3 76 0.4 1.6
9 23 Caucasian þ 720 3 835 0.5 1.5
10 26 Caucasian þ þ n.a. c.3428A> G p.E1143G 3 130 1.2 1.2
11 33 Caucasian þ 30 c.3428A> G p.E1143G 3 860 1.0 n.a.
12 33 Caucasian þ 1617 3 66 1.7 1.0
13 36 Hispanic þ 314 c.3708G> T p.Q1236H 2 2947 7.7 1.7
14 36 Caucasian þ 51 4 106 32.0 1.5
15 36 Caucasian þ 85 2 831 13.1 0.9
16 41 Caucasian þ 147 3 142 22.4 2.0
17 47 Caucasian þ 31 c.3708G> T p.Q1236H 2 90 0.5 2.1
Causality assessment key: 2, highly likely (75%-95% likely); 3, probable (50%-75% likely); 4, possible (25%-50% likely); or 5, unlikely (5%-25% likely). ALT, se-
rum alanine transferase; INR, international normalized coagulation ratio; n.a., not available.
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(MTND1) relative to the nuclear-encoded B2M
(AC025270) by real-time polymerase chain reaction
(PCR) (iQ Sybr Green, BioRad ICycler, CA).10
MtDNA deletions were detected by long-range PCR.
Functional Studies in Mammalian Cell
Models. Human hepatocyte cell lines from patients
with POLG variants are not available. Given the direct
toxic effect of VPA on skeletal muscle,11 we studied
human primary myoblasts and myotubes from a
p.Q1236H heterozygote, and a compound heterozy-
gous for p.A467T/p.K1191N with AHS with local
ethical approval (not DILIN subjects). Muscle cell cul-
ture was carried out as described.12 Both cell types
were treated with VPA (2, 10, 50, 100 mM) for up to
10 days. To induce mtDNA depletion mimicking the
depletion seen in AHS due to POLG mutations, myo-
blasts were treated with ethidium bromide (EtBr 50
ng/mL) for up to 10 days and myotubes with 300 lM
Didanosine (Sigma) or 300 lM Stavudine (Sigma) for
3 days prior to and 6 days during differentiation.12
Trypan blue-negative (viable) cells were counted using
a Mod-Fuchs hemocytometer. Apoptosis was deter-
mined using the Roche Apoptosis ladder kit. Cyto-
chrome c oxidase (COX) activity was evaluated histo-
chemically on day 10, and intermediary metabolites of
fatty acid b-oxidation were analyzed by tandem mass
spectrometry in culture media collected at days 0, 5,
and 10.13 All cell culture studies were done in tripli-
cate (Fig. 2A).
Functional Studies in Yeast. MIP1-human POLG
chimera (MIP1C allele) was constructed through sub-
stitution of nucleotides 2911-2964 of MIP1661T wild-
type (wt) allele14 with nucleotides 3658-3709 of
POLG encoding sequence. p.Q1236H was introduced
by site-specific mutagenesis. Frequency of petite
mutants and of erythromycin resistant (EryR) mutants
were measured as described.14
Results
Genetic Variation in POLG Is Common in
Patients with VPA Hepatotoxicity. POLG substitu-
tions were identified in 8 of the 17 patients with
suspect VPA-induced hepatotoxicity (Fig. 1A). One
harbored compound heterozygous mutations:
c.1399G> A/p.A467T, predicted to change alanine to
threonine in the linker region of the protein (p.A467T);
and c.911T>G predicted to alter a conserved leucine to
an arginine residue in the exonuclease region of polc
(p.L304R, Fig. 1b), previously reported in AHS. This
patient was prescribed VPA for unexplained seizures
and was known to have a peripheral neuropathy and
clumsiness. With hindsight, these features were the first
stage of the AHS, although this was not obvious on
clinical presentation. This patient required a liver trans-
plant following his initial exposure to VPA and then
developed intractable seizures leading to an early death,
highlighting the importance of identifying patients
at risk of VPA hepatotoxicity before commencing
treatment.
The remaining seven (41%) had a single heterozy-
gous POLG substitution. Five harbored c.3708G>T,
predicted to alter a glutamine in the polymerase do-
main (p.Q1236H, Fig. 1C), and two harbored
c.3428A>G, predicted to alter a glutamic acid in the
polymerase domain (p.E1143G, Fig. 1D). Both the
frequency of p.Q1236H (P ¼ 1.9  104) and the
combined frequency of p.Q1236H and p.E1143G (P
¼ 5.1  107) were significantly greater than in eth-
nically matched population controls (n ¼ 968 alleles),
giving a combined odds ratio (OR) ¼ 23.6 (95%
Fig. 1. (A) Gene structure of POLG showing the location of the (B) c.911T>G/p.L304R, c.1399G>A/p.A467T, (C) c.3708G>T/p.Q1236H,
and (D) c.3428A>G/p.E1143G substitutions. The exonuclease domain extends from amino acid residue 1 to 418. The polymerase domain
extends from amino acid residue 756 to 1239. The linker region lies between amino acid residues 418 and 756.
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confidence interval [CI] ¼ 8.4-65.8) (Supporting
Information Table S1). The strongest association was
in patients where VPA-induced liver toxicity was
highly likely (1 variants in 4/6, or 66%), and likely
(4/8, or 50%) compared to unlikely (0/2 or 0%).
Functional Consequences of the p.Q1236H
Substitution. The functional effects of p.Q1236H
have not been previously studied. We therefore con-
structed a Polg-Mip1 chimera (Mip1C) in the model
system yeast Saccharomyces cerevisiae in which 971-988
amino acids of Mip1 were substituted with the corre-
sponding 1220-1237 amino acids of polc (Fig. 2B).
This was mutagenized to introduce the substitution
p.Q1236H. The mip1CQ1236H strain showed a 1.5-
fold increase in petite frequency (18.0% [61.3] versus
12.4% [61.6]) (Fig. 2C), indicating extended mtDNA
mutability; and a 2-fold increase of EryR mutant fre-
quency, indicating increased mtDNA point mutability,
(19.7  108 [62.0] versus 10.9  108 [61.2]).
p.Q1236H is therefore highly likely to alter human
polc function. However, treatment with sublethal con-
centrations of VPA (1, 2, 5, 8, and 10 mM) did not
alter the yeast phenotype. The functional effects of
p.E1143G have been previously described both in
yeast and in vitro.14,15 In yeast, a 2-fold increase of
extended mutability was observed in a strain expressing
the mutant version of Mip1.14 In vitro, purified polc
harboring the p.E1143G mutation showed slightly
increased catalytic efficiency and intrinsic stability, but
also a reduced thermostability.15 The phenotype of
both substitutions is mild, explaining why these alleles
are common throughout the world (p.Q1236H
8.6%, and p.E1143G 4%). p.Q1236H and
p.E1143G may only be disadvantageous in specific
contexts, such as exposure to VPA.
No Evidence of a Secondary mtDNA Defect in
Whole Blood. Given the role of POLG in mtDNA
replication we looked for evidence of a qualitative or
quantitative defect of mtDNA in whole-blood cellular
mtDNA because liver tissue was not available from the
affected individuals. No mtDNA deletions were
detected by long-range PCR and the mtDNA content
was no different to age-matched controls (83.9 copies/
cell, standard deviation [SD] 58.8; versus 85.8, SD
28.3; Supporting Information Fig. 1A).
Cellular Effects of Sodium Valproate. Following
treatment for 10 days with therapeutically relevant doses
of VPA (2 and 10 mM) no significant decrease in
mtDNA content was observed (Fig. 3A), nor detectable
mtDNA deletions (Supporting Information Fig. 1b)
despite the observed cell death. Treatment of control
and patient myoblasts with the highest tolerated doses
of VPA (50 and 100 mM) still showed no depletion
of mtDNA but compromised cell proliferation,
with extensive cellular ballooning, vacuolization, and
detachment within 3 days of treatment (Supporting
Information Fig. 2). The presence of mtDNA deletions
was not investigated in these cells due to the short culture
Fig. 2. (A) Alignment of C-terminal stretch of human polc and the corresponding stretch of yeast Mip1. Q1236 amino acid is in bold; the
region which is changed in Mip1C is underscored. (B) Linear representation of polc, Mip1, Mip1C, and Mip1CQ1236H organization. Q1236 amino
acid is in bold. (C) Petri dish images showing the normal and petite colonies from the parental (Mip1C) and the Mip1CQ1236H strain (bottom).
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period, making the appearance of deletions highly
unlikely. By contrast, EtBr-treated cells grown in parallel
showed the expected decrease in mtDNA content after 10
days but no defect of cellular proliferation and no evidence
of cell death (Fig. 3B). There was no evidence of apoptosis
in any of the cell lines after 10 days of treatment. Multiple
mtDNA deletions were not detected in any of the cell pel-
lets, there were no differences in COX activity observed,
and b-oxidation metabolites remained within normal lim-
its (Supporting Information Table 2). We therefore
extended our studies to postmitotic myotubes, which
more closely model mtDNA depletion in vivo.12 MtDNA
levels were significantly lower in AHS and Q1236H myo-
tubes than in controls (Fig. 3C). To determine whether
mtDNA depletion itself predisposes to further mtDNA
loss after VPA exposure, we depleted the myotubes with
didanosine and stavudine, which induce less severe myo-
tube mtDNA depletion than EtBr.12 MtDNA depletion
levels in Q1236H myotubes were less than in controls,
and similar to the AHS cell lines, but there was no further
decrease in mtDNA content with the addition of 10 mM
VPA (Fig. 3C).
Discussion
VPA is a branched medium chain fatty acid known
to inhibit mitochondrial b-oxidation,16 possibly through
the microsomal production of toxic metabolites includ-
ing 4-ene-VPA,17 or cytosolic and mitochondrial CoA
sequestration effects.18 However, we saw no evidence of
a b-oxidation defect, making this mechanism unlikely in
this context. We also saw no evidence of a secondary
mtDNA defect, despite the VPA dose-related growth in-
hibition and cell death. By contrast, treating identical
cell lines with EtBr, didanosine, or stavudine caused pro-
found but recoverable mtDNA depletion without cell
death. VPA toxicity is therefore unlikely to be mediated
through a direct effect on mtDNA, explaining why we
did not observe a COX defect in VPA-treated cells.
Although it is possible that these aspects are specifically
deranged in the liver, we observed the morphological
characteristics of VPA hepatotoxicity in human myo-
blasts,3 implicating the same mechanism in our in vitro
model. Moreover, an elevated serum creatine kinase in
patients with VPA toxicity points to a similar direct
toxic effect on skeletal muscle.11
Unlike mature skeletal muscle and brain, the liver
can proliferate in response to damage, and there is
clear evidence of hepatocyte proliferation in patients
with AHS. We have shown that treatment with 2 and
10 mM VPA impairs cellular proliferation in vitro,
and that p.Q1236H increases mtDNA mutability in
yeast and may decrease mtDNA copy number in myo-
tubes. The yeast system is a proven method to study
the effects on mtDNA of both strong and weak POLG
mutations, such as p.E1143G, whose effects are very
mild and cannot easily be observed in higher eukar-
yotes.14 After a limited number of cell divisions most
yeast mitochondria are homoplasmic, as the hetero-
plasmic state is always transient in S. cerevisiae.14
Fig. 3. (a) Ratio of mtDNA to nuclear DNA for each cell line follow-
ing 10 days of treatment with either 2 mM VPA, 10 mM VPA, 50 ng/
mL ethidium bromide (EtBr), or untreated. AHS ¼ p.A467T/p.K1191N
compound heterozygote. (b) Relationship between mtDNA level and
cell viability after 10 days of treatment. For comparison, mtDNA ratios
(mtDNA/nDNA) are represented as columns on the left-hand y-axis
and cell count (106) as a line plot on the right-hand y-axis. VPA ¼
sodium valproate. EtBr ¼ ethidium bromide. AHS ¼ p.A467T/
p.K1191N compound heterozygote. (c) Ratio of mtDNA to nuclear DNA
for each myotube cell line following 9 days of treatment with/without
300 lM didanosine (D) or stavudine (S) and additionally with/without
10 mM VPA. MB ¼ myoblasts, MT ¼ myotubes, AHS ¼ p.A467T/
p.K1191N compound heterozygote, VPA ¼ sodium valproate. Error
bars ¼ SD in all panels.
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Therefore, conditions that cause increased mtDNA
mutability, even at a low extent, lead to an increase of
respiratory deficient cells (i.e., petite mutants) after
only a few generations. For the p.Q1236H mutation
we observed a small but significant increase in
extended mtDNA mutability determined as an increase
in petite frequency. Observation of this effect in a yeast
model predicts that a similar effect would occur in
human cells, resulting in mtDNA copy number reduc-
tion, as observed in myotubes harboring this mutation.
This raises the possibility that both mechanisms inde-
pendently compromise the regenerative capacity of the
liver, thus inhibiting the endogenous capacity for liver
repair in response to an external insult. For VPA, this
could be through the inhibition of histone deacety-
lases, which regulate gene expression by relaxing chro-
matin structure and facilitating access to DNA by the
transcriptional machinery.19
In this study, over 50% (8/14) of patients with proba-
ble VPA hepatotoxicity had heterozygous POLG substi-
tutions associated with >20-fold increased risk of VPA-
induced liver injury, seven of whom harbored previously
described single nucleotide polymorphisms; p.Q1236H
and p.E1143G . Here we show that p.Q1236H is not
phenotypically neutral, with histidine at position 1236
increasing both mtDNA deletion frequency and point
mutability frequency in yeast. However, the phenotype
of both substitutions is mild, explaining why these alleles
are common throughout the world (p.Q1236H 8.6%,
and p.E1143G 4%). This suggests p.Q1236H and
p.E1143G are only disadvantageous in specific contexts,
such as exposure to VPA. Screening for functional
POLG substitutions will minimize the risk of fulminant
liver failure in patients exposed to VPA.
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